Extended Data Table 1 Safety of FMT in combination with ICIa

From: Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial

  1. aOnly AEs with incidence ≥10% are shown (unless grade ≥2)
  2. bAdverse events reported occurred following FMT administration and prior initiation of immune checkpoint inhibitor (ICI) therapy.
  3. cPatient 101-025 (NSCLC) experienced a grade 4 increase in lipase levels, the symptoms were grade 1 abdominal pain with no abnormality on CT scan.
  4. dAdverse events reported occurred following FMT administration and prior initiation of immune checkpoint inhibitor (ICI) therapy.
  5. Patient 101-011 (Cutaneous melanoma) experienced a heart attack, which resulted in death. This incident was reported outside of the designated reporting period. The event was reviewed by the Data Safety Monitoring Board which concluded that it was not related to FMT or ICI.
Back to article page